Key result
Leadless pacemakers resolve long-term pacing morbidities by eliminating transvenous leads and subcutaneous pockets.
Why the study?
Do leadless pacemakers improve safety and efficacy outcomes compared to conventional transvenous pacemakers in patients requiring cardiac pacing?
Do leadless pacemakers improve safety and efficacy outcomes compared to conventional transvenous pacemakers in patients requiring cardiac pacing?
Leadless pacemakers have evolved into a primary therapeutic standard that eliminates transvenous lead complications, with future advancements focusing on wireless multi-component networks and energy harvesting.
Answers are grounded in this paper and cite their sources.
May support leadless pacemakers to reduce lead complications; leaves open need for RCTs to confirm as standard.
Background: Conventional transvenous pacemakers (TVPs) have been the gold standard for bradyarrhythmia management for over six decades. However, transvenous leads and the subcutaneous pocket remain the primary sources of acute and chronic morbidity. Recent large-scale meta-analyses confirm that leadless pacemakers (LPMs) systematically eliminate pocket infections and significantly reduce lead-induced valvular complications. Aim: The primary objective of this review is to evaluate the clinical safety, efficacy, and technological progression of leadless pacing systems - from first-generation devices (e.g., Nanostim, Micra VR) to contemporary multi-component modular networks, resynchronization therapies, and novel physiologic sensors. Methods: A comprehensive literature search was performed across major medical databases (PubMed, EMBASE, Cochrane Library) for studies published up to May 2026, focusing on randomized controlled trials, large prospective registries, and clinical updates. Results: First-generation single-chamber ventricular LPMs demonstrated an excellent long-term safety profile in global registries, outperforming historical transvenous cohorts. The contemporary era is characterized by major structural breakthroughs: advanced accelerometer algorithms for mechanical atrial tracking (Micra AV) and dual-chamber leadless pacing systems (AVEIR DR) utilizing intrabody conductive communication for implant-to-implant (i2i) synchronization. Advanced features now include temperature-based rate response and median battery longevity exceeding 15 years. Conclusions: Leadless pacemakers have evolved from a niche solution into a primary therapeutic standard. The future of this field relies on multi-component modular networks (pairing LPMs with subcutaneous ICDs), entirely leadless cardiac resynchronization therapy (CRT) utilizing ultrasound acoustics, and the pursuit of energy-harvesting technologies.
No takes yet. Share an insight, caveat, or question.
Sobantka et al. (2026) conducted a review in Bradyarrhythmia. Leadless pacemakers vs. Conventional transvenous pacemakers was evaluated. Leadless pacemakers have successfully transitioned into a primary therapeutic standard that eliminates transvenous leads and subcutaneous pockets, resolving significant long-term pacing morbidities.
Synapse has enriched 10 related papers. Consider them for comparative context: